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Fast-track  Diagnostics  respiratory  pathogens  (FTDRP)  multiplex  real-time  RT-PCR  assay  was  compared
with  in-house  singleplex  real-time  RT-PCR  assays  for detection  of  16  common  respiratory  viruses.  The
FTDRP  assay  correctly  identiﬁed  26  diverse  respiratory  virus  strains,  35  of 41 (85%) external  quality
assessment  samples  spiked  with  cultured  virus  and  232  of 263  (88%)  archived  respiratory  specimens  that
tested  positive  for respiratory  viruses  by  in-house  assays.  Of 308  prospectively  tested  respiratory  speci-
mens selected  from  children  hospitalized  with  acute  respiratory  illness,  270  (87.7%)  and  265 (86%)  were
positive  by  FTDRP  and  in-house  assays  for one  or  more  viruses,  respectively,  with  combined  test  results
showing  good  concordance  (K  = 0.812,  95%  CI  =  0.786–0.838).  Individual  FTDRP  assays  for adenovirus,  res-
piratory  syncytial  virus  and  rhinovirus  showed  the  lowest  comparative  sensitivities  with  in-house  assays,
with most  discrepancies  occurring  with  specimens  containing  low  virus  loads  and  failed  to  detect  some
rhinovirus  strains,  even  when  abundant.  The  FTDRP  enterovirus  and human  bocavirus  assays  appeared
to  be  more  sensitive  than  the  in-house  assays  with  some  specimens.  With  the  exceptions  noted  above,
most  FTDRP  assays  performed  comparably  with  in-house  assays  for most  viruses  while  offering  enhanced
throughput  and  easy  integration  by  laboratories  using  conventional  real-time  PCR  instrumentation.
Published by Elsevier B.V.
1. Introduction
Respiratory viruses are among the most important causes of
human morbidity and mortality worldwide (Nair et al., 2010; Pavia,
2011). Clinically indistinguishable, respiratory virus infections
require accurate laboratory diagnosis to guide treatment effec-
tively and prevention decisions. Polymerase chain reaction (PCR)
and other molecular assays are now routinely used for diagnosis
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of respiratory virus infections (Beck and Henrickson, 2010; Kehl
and Kumar, 2009), but the large and increasing number of viruses
makes laboratory testing with individual (singleplex) virus assays
challenging. Conversely, multiplex PCR assays that combine multi-
ple individual assays in a single reaction facilitate more rapid, high
throughput and cost-effective testing and are generally preferred
in the clinical setting (Elnifro et al., 2000; Jansen et al., 2011).
Numerous laboratory-developed and commercial multiplex
PCR assays using different ampliﬁcation platforms have been
described for respiratory viruses and have been generally shown to
be superior to traditional diagnostic methods, such as virus culture
and antigen detection for sensitive and speciﬁc detection of respi-
ratory viruses (Arens et al., 2010; Bibby et al., 2011; Brittain-Long
et al., 2010; Caliendo, 2011; Gadsby et al., 2010; Kim et al., 2009;
Lamson et al., 2006; Mahony et al., 2007; Raymond et al., 2009).
The US Food and Drug Administration (FDA) has cleared recently
two commercial assays, the xTAG® RVP Fast (Luminex Molecular
Diagnostics, Austin, TX) and FilmArray® Respiratory Panels (Idaho
Technology Inc., Salt Lake City, Utah) (Rand et al., 2011), for in-
vitro diagnostic use for multiplex detection of respiratory viruses.
0166-0934/$ – see front matter. Published by Elsevier B.V.
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However, many of these assays are costly, require specialized lab-
oratory equipment and use highly multiplexed reactions that may
be deﬁcient in individual assay performance and can be difﬁcult
to modify without extensive assay reoptimization (Gunson et al.,
2008).
The FTD respiratory pathogens (FTDRP) multiplex assay kit
(Fast-track Diagnostics, Luxembourg) uses standard commercial
one-step reverse transcription (RT)-PCR hydrolysis probe chem-
istry and common real-time PCR instrumentation. The FTDRP assay
consists of 5 discrete primer/probe mixes that together cover 16
common human respiratory viruses. This study reports the results
of a comparison of the FTDRP multiplex assay with a panel of val-
idated in-house singleplex real-time RT-PCR assays developed at
the Centers for Disease Control and Prevention (CDC).
2. Materials and methods
2.1. Viruses and specimens
Virus isolates and archived clinical specimens were obtained
from CDC collections acquired during routine surveillance and out-
break investigations. These included 26 laboratory reference virus
strains and ﬁeld isolates and 265 geographically (U.S., Central and
South America and Africa) and compositionally diverse specimens
[nasopharyngeal and oropharyngeal swabs (223), nasal washes and
aspirates (21), sputum (1), lung autopsy tissue (1) and unidenti-
ﬁed (19)] collected from children and adults with acute respiratory
illnesses (ARIs) acquired between 2008 and 2011 and previously
testing positive for respiratory viruses by the in-house singleplex
assays. All residual samples and extracts were stored at −70 ◦C.
Whenever possible, archived specimens were selected to achieve a
proportional representation of viral loads. Forty-six mock human
specimens spiked with moderate-to-low concentrations of virus
were available from the 2010 Quality Control for Molecular Diag-
nostics (QCMD, Glasgow, Scotland) external quality assessment
(EQA) programs for rhinovirus/coronavirus, adenovirus, parain-
ﬂuenza viruses, human metapneumovirus/respiratory syncytial
virus, and inﬂuenza A & B viruses (Wallace, 2003). Pooled nasal
wash specimens from 20 consenting healthy new military recruits
was kindly provided by Dr. Lisa Lott, Eagle Applied Sciences, L.L.C.,
San Antonio, TX. Finally, a subset of 308 nasopharyngeal aspirates
(NPAs) from an etiologic study of 1162 children < 2 years of age
hospitalized with ARI at a tertiary hospital in São Paulo, Brazil,
between March 2008 and September 2010, were selected from the
seasonal peaks of respiratory virus circulation for each of the study
years based on local surveillance data. The NPAs were collected
directly into liquid nitrogen, aliquoted and transferred to −70 ◦C
and retained until retrieved for this study. This study was  approved
by institutional review boards at the University of São Paulo and
Santa Casa de Misericórdia de São Paulo Hospital, Brazil, and CDC.
2.2. Total nucleic acid extraction
Total nucleic acid (TNA) extracts were prepared from samples
using the NucliSENS® easyMAG® (bioMérieux). Because of their
multiple study origins and testing histories, residual archived spec-
imen extraction volumes varied from 100 to 300 L and TNA elution
volumes from 55 to 100 L. RNase-free water was added to a few
archived extracts (≤2-fold dilution) to obtain sufﬁcient volume for
comparison testing. For prospectively tested nasal aspirate speci-
mens, 300 L of each sample was extracted and the TNA recovered
in 210 L of elution buffer which was then split into 3 aliquots and
frozen at −70 ◦C until testing. All extracts were subjected to iden-
tical freeze-thaw cycles for comparison testing. All extracts were
Table 1
Comparison of FTDRP and in-house assays with 26 virus isolates.
Virus (strain) In-house (Ct) FTDRP (Ct)a
AdV C1 (Ad.71) Pos (13.7) Pos (16.7)
AdV C5 (Ad.75) Pos (18.4) Pos (20.1)
AdV B7 (SA-104) Pos (13.8) Pos (18.8)
AdV B14 (deWit) Pos (20.8) Pos (23.3)
AdV E4 (RI-67) Pos (15.2) Pos (18.2)
CoV 229E Pos (10.3) Pos (13.2)
CoV OC43 Pos (13.0) Pos (14.9)
CoV SARS (Urbani) Pos (19.2) n/ac
EV, echovirus 6b Pos (21.3) Pos (15.8)
EV, echovirus 11b Pos (16.3) Pos (15.5)
EV, enterovirus 68b Pos (21.3) Pos (24.6)
HMPV A (CAN 97-83) Pos (15.0) Pos (17.0)
HMPV B (CAN 98-75) Pos (18.3) Pos (21.2)
Inf A H1N1 (A/California/09) Pos (14.7) Pos (14.8)
Inf A H2N1 (A/Japan/57) Pos (27.3) Pos (24.4)
Inf B (B/Shanghai/99) Pos (14.6) Pos (15.1)
PIV 1 (C35) Pos (16.6) Pos (19.1)
PIV 2 (Greer) Pos (16.9) Pos (15.8)
PIV 3 (C-43) Pos (15.2) Pos (16.3)
PIV 4a (M-25) Pos (16.7) Pos (19.5)
PIV 4b (CH 19503) Pos (21.5) Pos (21.1)
PeV 1b Pos (16.0) Pos (16.4)
RSV A (Long) Pos (15.0) Pos (15.7)
RSV B (CH 93-18B) Pos (15.1) Pos (16.7)
RV A1a Pos (13.4) Pos (15.3)
RV B14 Pos (15.7) Pos (32.0)
a Unless otherwise indicated, all other FTDRP assays were negative.
b FTDRP EV/PeV assay does not distinguish between EV and PeV.
c FTDRP SARS CoV assay not available (n/a).
conﬁrmed positive for human RNase P gene by real-time RT-PCR
before inclusion in the study.
2.3. FTDRP multiplex assay
The FTDRP multiplex real-time RT-PCR assay (ver.5, cat. no.
FTD 2-96/12) consists of 5 separate primer/probe mixes covering
16 human respiratory viruses and brome mosaic virus (BMV), an
RNA plant virus that serves as an internal extraction control when
spiked into the sample (virus provided); mix #1: inﬂuenza A virus
(Inf A), inﬂuenza B virus (Inf B), BMV; mix  #2: coronavirus (CoV)
NL63, 229E and OC43 and enterovirus/parechovirus (EV/PeV); mix
#3: parainﬂuenza virus (PIV) 2, 3 and 4; mix #4: PIV 1, human
metapneumovirus (HMPV) and human bocavirus (HBoV); mix #5:
rhinovirus (RV), respiratory syncytial virus (RSV) and adenovirus
(AdV). Individual assays within each pool are distinguished by use
of different probe ﬂuorophores, with the exception of the EV and
PeV assays, where both probes are ROX-labeled and therefore can-
not be distinguished. Each kit also contains a positive plasmid
control pool and detailed instructions on test performance. The
FTDRP assay was performed following the manufacturer’s recom-
mendations. Brieﬂy, 194 L of 2× RT-PCR buffer was  combined with
23.3 L of each primer/probe pool and 15.5 L of 25× enzyme mix
(AgPath-IDTM One-Step RT-PCR Kit, Applied Biosystems), and 15 L
of each mixture was  then added to 14 wells of a PCR plate (12
sample reactions plus one positive and one negative virus control).
Ten L of sample TNA extract or controls were then added to the
respective wells of each primer/probe pool. The following cycling
conditions were performed on a 7500 Fast Dx Real-Time PCR Instru-
ment (Applied Biosystems): 15 min at 50 ◦C, 10 min at 95 ◦C and 40
cycles of 8 s at 95 ◦C and 34 s at 60 ◦C. Threshold cycle (Ct) values
were determined by manually adjusting the ﬂuorescence baseline
to fall within the exponential phase of the ampliﬁcation curves and
above any background signal. A positive test result was consid-
ered a well-deﬁned curve that crossed the threshold cycle within
40 cycles. Positive and negative virus plasmid controls provided in
the kit were included in all runs to monitor assay performance. The
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Table  2
Comparison of FTDRP and in-house assays with 46 samples from 5 QCMD EQA programs.
QCMD EQAa Virus QCMD Keyb In-house (Ct) FTDRP (Ct)
Adenovirus (AdV)
ADV10-02 AdV F41 Pos (113) Neg/Pos (39.6)c Pos (39.4)
ADV10-03 AdV C1 Pos (64121) Pos (30.9) Pos (29.2)
ADV10-04 AdV E4 Pos (767) Pos (36.7) Pos (35.1)
ADV10-06 AdV C1 Pos (4055) Pos (34.0) Pos (32.0)
ADV10-08 AdV B34 Pos (1225) Pos (34.0) Neg/Negc
ADV10-07 No virus Neg Neg Neg
Inﬂuenza virus (Inf)
INFRNA 09-01 Inf A subtype H1 Pos (29.4) Pos (29.4) Pos (28.9)
INFRNA 09-02 Inf A subtype H3 Pos (31.4) Pos (28.8) Pos (29.7)
INFRNA 09-03 Inf B Pos (39.2) Pos (38.3) Pos (38.2)
INFRNA 09-04 Inf A subtype H1vd Pos (28.7) Pos (28.7) Pos (25.7)
INFRNA 09-06 Inf A subtype H1 Pos (27.9) Pos (28.7) Pos (27.8)
INFRNA 09-07 Inf B Pos (32.1) Pos (30.3) Pos (27.5)
INFRNA 09-09 Inf A subtype H1vd Pos (32.1) Pos (28.8) Pos (28.7)
INFRNA 09-10 Inf A subtype H1 Pos (29.4) Pos (29.9) Pos (29.1)
INFRNA 09-11 Inf A subtype H1 Pos (33.1) Pos (33.5) Pos (33.0)
INFRNA 09-12 Inf A subtype H3 Pos (35.6) Pos (33.3) Pos (33.0)
INFRNA 09-05 No virus Neg Neg Neg
Parainﬂuezavirus (PIV)
PINF10-01 PIV 1 Pos (33.1) Pos (32.7) Pos (38.1)
PINF10-02 PIV 4 Pos (31.9) Pos (35.2) Pos (33.5)
PINF10-03 PIV 1 Pos (31.0) Pos (31.1) Pos (33.8)
PINF10-06 PIV 3 Pos (34.5) Pos (25.7) Pos (23.7)
PINF10-07 PIV 2 Pos (28.2) Pos (24.0) Pos (21.3)
PINF10-08 No virus Neg Neg Neg
Respiratory syncytial virus (RSV) & Human metapneumovirus (HMPV)
MPV.RSV10-01 RSV A Pos (38.4) Pos (36.7) Neg/Pos (36.8)c
MPV.RSV10-02 RSV B Pos (37.1) Pos (31.7) Neg/Pos (33.1)c
MPV.RSV10-04 RSV A Pos (33.4) Pos (31.1) Pos (30.7)
MPV.RSV10-09 RSV B Pos (39.9) Pos (34.8) Neg/Pos (37.3)c
MPV.RSV10-10 RSV B Pos (32.4) Pos (24.6) Pos (25.4)
MPV.RSV10-11 RSV A Pos (37.3) Pos (33.7) Pos (36.5)
MPV.RSV10-03 HMPV B2 Pos (35.5) Pos (29.7) Pos(32.5)
MPV.RSV10-05 HMPV B2 Pos (38.5) Pos (32.8) Pos (34.2)
MPV.RSV10-07 HMPV A1 Pos (39.3) Pos (34.9) Neg/Pos (39)c
MPV.RSV10-08 HMPV A1 Pos (33.2) Pos (29.1) Pos (33.2)
MPV.RSV10-12 HMPV B2 Pos (35.6) Pos (30.0) Pos (32.2)
MPV.RSV10-06 No virus Neg Neg Neg
Rhinovirus (RV) & Coronavirus (CoV)
RV.CV10-01 RV B42 Pos (29.6) Pos (26.9) Pos (36.7)
RV.CV10-02 RV A8 Pos (25.8) Pos (22.5) Pos (24.0)
RV.CV10-03 RV B72 Pos (22.9) Pos (21.5) Neg/Negc
RV.CV10-05 RV A90 Pos (32.6) Pos (28.7) Pos (31.6)
RV.CV10-07 RV A16 Pos (30.5) Pos (27.5) Pos (30.3)
RV.CV10-09 RV A16 Pos (34.1) Pos (30.9) Pos (33.3)
RV.CV10-04 CoV 229E Pos (28.5) Pos (27.9) Pos (26.6)
RV.CV10-08 CoV 229E Pos (35.0) Pos (34.0) Pos (32.5)
RV.CV10-06 CoV OC43 Pos (31.1) Pos (32.6) Pos (32.2)
RV.CV10-10 CoV NL63 Pos (26.9) Pos (25.7) Pos (24.1)
RV.CV10-11 EVe Neg Neg Neg
a QCMD EQA, 2010 Quality Control for Molecular Diagnostics External Quality Assessment program samples.
b QCMD test results; Ct values (RV/CoV, PIV, RSV/HMPV) and genome copies/mL (AdV). QCMD Ct values should not be used for method comparison or as a target for
individual laboratory assessment.
c Original and repeat result.
d Inf A subtype H1v = new variant pandemic H1N1 strain.
e QCMD EQA negative RV control sample contained coxsackievirus A1.
BMV  internal control was spiked into clinical specimens to monitor
sample extraction and reverse transcription. Previously extracted
TNA samples were evaluated for RNase P only.
2.4. In-house singleplex assays
In-house singleplex real-time RT-PCR assays for RSV, HMPV,
PIV1-4, RV, AdV, HBoV and CoVs (229E, OC43, NL63, HKU1, SARS-
CoV) as previously described (Dare et al., 2007; Emery et al., 2004;
Fry et al., 2010; Heim et al., 2003; Kodani et al., 2011; Lu et al., 2006,
2008; Morgan et al., 2012) were performed on a MX3000P QPCR
System (Agilent Technologies) using AgPath-IDTM One-Step RT-PCR
reagents (Applied Biosystems) with the following cycling condi-
tions: 45 ◦C for 10 min, 95 ◦C for 10 min  and 45 cycles of 95 ◦C for 15 s
and 55 ◦C for 1 min. Primer/probe sequences are available from D.E.
on request. The in-house EV and PeV assays as modiﬁed from previ-
ous reports (Kilpatrick et al., 2009; Nix et al., 2008) were performed
on a MX3000P QPCR System using the SuperScript III Platinum®
One-Step Quantitative RT-PCR System reagents (Invitrogen) with
the following cycling conditions: 50 ◦C for 30 min, 95 ◦C for 5 min
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and 45 cycles of 95 ◦C for 15 s, 55 ◦C (EV) or 58 ◦C (PeV) for 45 s and
72 ◦C for 10 s. Universal Inf A and Inf B assays were performed on a
7500 Fast Dx Real-Time PCR Instrument with SDS software ver. 1.4
(Applied Biosystems) using the SuperScript III Platinum® One-Step
Quantitative RT-PCR System with the following cycling conditions:
50 ◦C for 30 min, 95 ◦C for 2 min  and 45 cycles of 95 ◦C for 15 s and
55 ◦C for 30 s (Stephen Lindstrom, CDC, personal communication).
Following standard operating procedures, all in-house assays
were performed in 25 L ﬁnal reaction volumes containing 5 L of
sample TNA extract. A positive test result was considered a well-
deﬁned curve that crossed the threshold cycle within 40 cycles.
Positive and negative virus RNA transcript or whole virus extract
controls were included in all runs to monitor assay performance.
2.5. Statistics
Percent sensitivity and speciﬁcity of the FTDRP assay for
prospectively collected specimens were calculated using the in-
house assays as the reference standard. Agreement between assays
was measured using the Kappa statistic (Cohen, 1960) where 0
indicates no agreement and 1 indicates perfect agreement.
3. Results
3.1. Virus isolates
The FTDRP assay was ﬁrst evaluated with undiluted TNA from
cultures of 26 respiratory virus strains corresponding to most
assays in the multiplex to assess assay speciﬁcity and virus strain
inclusivity (Table 1). Although no FTDRP assay for SARS-CoV was
available, this virus was tested to assess the speciﬁcity of the other
FTDRP CoV assays. HBoV and CoV NL63 and HKU1 isolates were
not available for testing. Positive results were obtained with both
assays for all viruses with no cross-reactions detected. FTDRP and
in-house assay results were within 3Ct values for 22 (88%) of the
viruses tested. Notably, the FTDRP RV assay gave a substantially
higher Ct value ( 16.3Ct) with one RV isolate (RV-B14). Serial
dilutions of RV-B14 TNA showed the FTDRP assay to be >1000-fold
less sensitive than the corresponding in-house assay with this virus
strain (data not shown).
3.2. Pooled human respiratory specimens
The speciﬁcity of the FTDRP assay was further evaluated
with pooled nasal wash samples from 20 consenting normal
healthy adults to represent diverse microbial ﬂora in the human
respiratory tract. Positive results were obtained with the in-house
assays for RV (Ct 25.0), CoV 229E (Ct 35.1) and AdV (Ct 39.3) which
were conﬁrmed by alternate RT-PCR assays and sequencing. The
FTDRP assay was positive for RV (Ct 28.3) and CoV 229E (Ct 34.8),
but did not detect the AdV on initial or repeat testing. All other
in-house and FTDRP assays were negative.
3.3. QCMD EQA program samples
Forty-one mock respiratory samples spiked with low to mod-
erate levels of different viruses and 5 negative control samples
selected from 2010 QCMD EQA programs for HRV/CoV, AdV, PIV,
RSV/HMPV and Inf A/B, were tested to assess assay performance
against the reference QCMD assays (Table 2). Overall, expected
results were obtained with 40 (98%) and 35 (85%) of positive EQA
program samples with the in-house and FTDRP assays, respectively.
All program negative control samples were negative by both assays.
One sample (AdV10-02), with low concentration AdV-F41, was ini-
tially negative by the in-house assay, but positive on repeat testing.
The FTDRP assay gave expected results with all PIV (5), CoV (4) Inf Ta
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Table  4
Comparison of FTDRP and in-house assays with 32 archived respiratory specimens with sequence conﬁrmed rhinovirus (RV) or enterovirus (EV).
Virusa RV EV PeV EV/PeV
In-house (Ct) FTDRP (Ct) In-house (Ct) In-house (Ct) FTDRP (Ct)b
EV, enterovirus 68 Neg Neg Pos (31.1) Neg Pos (30.7)
EV,  enterovirus 68 Neg Neg Pos (28.9) Neg Pos (24.4)
EV,  echovirus 9 Neg Neg Pos (23.5) Neg Pos (23.4)
EV,  coxsackievirus B4 Neg Neg Pos (22.6) Neg Pos (21.6)
EV,  coxsackievirus B5 Neg Neg Pos (31.0) Neg Pos (27.1)
RV  A18 Pos (17.7) Pos (23.1) Neg Neg Neg
RV  A19 Pos (25.1) Pos (23.5) Neg Neg Neg
RV  A22 Pos (19.1) Pos (19.6) Neg Neg Neg
RV  A30 Pos (16.7) Pos (16.7) Neg Neg Neg
RV A30 Pos (20.3) Pos (23.6) Neg Neg Neg
RV A33 Pos (22.3) Pos (27.7) Neg Neg Neg
RV  A38 Pos (18.8) Pos (22.6) Neg Neg Neg
RV  A38 Pos (21.1) Pos (24.6) Neg Neg Pos (36.1)
RV  A49 Pos (19.5) Pos (18.1) Neg Neg Neg
RV  A58 Pos (17.7) Pos (20.2) Neg Neg Neg
RV  A76 Pos (23.2) Pos (29.6) Neg Neg Neg
RV  A68 Pos (22.8) Pos (22.6) Neg Neg Pos (31.4)
RV  A96 Pos (25.9) Pos (26.3) Neg Neg Neg
RV  B6 Pos (12.9) Pos (24.1) Neg Neg Neg
RV  B6 Pos (27.8) Neg Neg Neg Neg
RV  B6 Pos (25.1) Neg Neg Neg Neg
RV  B48 Pos (21.5) Neg Neg Neg Neg
RV  B97 + C Pos (28.3) Pos (29.5) Neg Neg Neg
RV  C Pos (23.2) Pos (22.9) Neg Neg Neg
RV  C Pos (26.8) Neg Neg Neg Neg
RV  C Pos (20.6) Pos (20.8) Neg Neg Neg
RV  C Pos (23.1) Pos (29.7) Neg Neg Neg
RV  C Pos (17.3) Pos (19.9) Negc Neg Pos (28.3)
RV  C Pos (20.0) Pos (21.5) Neg Neg Neg
RV  C Pos (18.7) Pos (28.7) Neg Neg Neg
RV  C Pos (18.6) Pos (25.5) Pos (31.6) Neg Pos (34.6)
RV  C Pos (23.4) Pos (28.2) Neg Neg Neg
a RV species A, B, C; no serotype-speciﬁc determination for RV species C.
b FTDRP EV/PeV assay does not distinguish between EV and PeV.
c Ct (41.4) above assay cutoff.
A (8) and Inf B (2) positive samples, and 3 of 6 (50%) RSV, 4 of 5
(80%) HMPV, 5 of 6 (83%) RV and 4 of 5 (80%) AdV positive samples.
RSV (MPV.RSV10-01, MPV.RSV10-02, MPV.RSV10-09) and HMPV
(MPV.RSV10-07) positive samples that were negative by FTDRP
assay had generally lower virus loads and were positive on repeat
testing. In contrast, EQA samples spiked with RV-B72 (RV.CV10-03)
and AdV-B34 (ADV10-08) were consistently negative and RV-B42
(RV.CV10-01) showed substantially higher Ct values ( 9.8Ct) by
the FTDRP RV assay.
3.4. Archived clinical specimens
Two hundred sixty-ﬁve diverse respiratory specimens that pre-
viously tested positive for respiratory viruses by in-house assays
were selected for comparison with the FTDRP assay. Of these, 263
were positive for at least one of the 16 assays available in the
FTDRP multiplex; two specimens positive for CoV HKU1 for which
there was no corresponding FTDRP assay were also tested to assess
the speciﬁcity of the other FTDRP CoV assays (Table 3). Because
of limited available sample volume, only FTDRP multiplex mixes
containing the virus-speciﬁc assay were performed and virus co-
detections by the other assays in each multiplex mix  were not
included in the analysis. All specimens were conﬁrmed positive
by in-house singleplex assays on retesting. The FTDRP assay iden-
tiﬁed all specimens that were positive for HBoV (2), CoV NL63 (8),
Inf A (17), Inf B (11), HMPV (26), PIV4 (12) and EV/PeV (5 EV and 3
PeV); >90% for PIV2 (12/13) and PIV3 (30/31); 85% for PIV1 (17/20);
79% for RV (37/47); 74% for RSV (23/31); and 68% for AdV (17/25).
Overall, the FTDRP assay identiﬁed correctly 88% of the archived
specimens positive for respiratory viruses by the in-house assays
and 97% of specimens with lower Ct values (<30). Two specimens
positive for CoV HKU1 by in-house singleplex assay were negative
by the FTDRP CoV 229E, OC43 and NL63 assays.
The FTDRP AdV, RSV and RV assays gave the lowest relative
sensitivities with the archived specimens at 68%, 74% and 79%,
respectively. With the exception of RV, most discrepancies occurred
with samples containing low levels of viral target. For example,
most FTDRP AdV false-negatives occurred with moderate to high
Ct value specimens (mean Ct 37.3; range 33.0–39.5), but this did
not appear to be associated with any particular AdV type. A wide
range of sequence-conﬁrmed AdV types were represented among
the archived specimens, including species B (types 3, 7 and 50), C
(types 2, 5, 6 and untyped) and F (types 40 and 41), suggesting that
the FTDRP AdV assay is inclusive for all recognized human AdV
types. In contrast, FTDRP RV assay failed to detect 5 RV positive
samples with low Ct values by the corresponding in-house assay.
To further assess the FTDRP RV and EV/PeV assays for virus
type/strain inclusivity and group exclusivity, 32 archived samples
with high RV (27) or EV (5) loads and typed by partial VP1 and/or
VP4/2 RT-PCR and sequencing (protocols available from X.L. on
request) were retested (Table 4). The FTDRP RV assay gave negative
results with 4 samples and was ≥10Ct values higher than the in-
house assay with 2 others, all species B or C RVs. The FTDRP EV/PeV
assay was also positive with 4 sequence-conﬁrmed RV positive
specimens of which 1 was also positive by the in-house EV assay;
a second sample also gave an exponential ﬂuorescence ampliﬁ-
cation curve with the in-house EV assay, but with a >40Ct value
and was  therefore classiﬁed as EV-negative based on test cutoff
criteria. Although EV was not detected in 2 of these samples by
VP4/2 RT-PCR, and PeV was not detected by the in-house assay, the
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presence of these viruses could not be ruled out deﬁnitively. Never-
theless, the most probable explanation for these results is that the
FTDRP and in-house EV assays cross-react with some RV strains.
Five sequence-conﬁrmed EV-positive samples were positive by the
FTDRP EV/PeV assay with no evidence of cross-reactions with the
RV and PeV assays.
3.5. Prospectively tested clinical specimens
Three hundred-eight nasopharyngeal aspirates selected from a
study of infants and young children hospitalized with acute res-
piratory infection were tested prospectively by both in-house and
FTDRP assays. Of these, 277 (89.9%) were positive for one or more
of the 16 viruses by either the in-house singleplex or FTDRP mul-
tiplex assays, with 270 (87.7%) positive by the in-house assay and
265 (86%) positive by FTDRP assay alone (Table 5). Overall, the in-
house and FTDRP assays showed good concordance (K = 0.812, 95%
CI = 0.786–0.838) (Table 6). As seen with the archived specimens,
however, the FTDRP AdV, RSV and RV assays gave consistently
lower detection rates than the corresponding in-house assays, at
43.7%, 72.5% and 75.5%, respectively, and missed some specimens
with high virus loads. Coincidently, these three assays are com-
bined in the same reaction mix  (mix #5) and had the highest
co-detection rate for these viruses by in-house assays at 41.9%; fol-
lowed by mix  #4 (PIV1, HBoV, HMPV) at 23.8%; mix  #2 (CoV 229E,
CoV OC43, CoV NL63, EV/PeV) at 16.3%; mix  #3 (PIV2, PIV3, PIV4)
at 7.3%; and mix  #1 (Inf A, Inf B) at 2.2%. Simultaneous presence
of multiple targets in the same specimen may  have led to compet-
itive inhibition of ampliﬁcation of less abundant targets and may
explain some loss of assay sensitivity.
The FTDRP HBoV assay appeared to be more sensitive than
the corresponding in-house assay (Lu et al., 2006) with specimens
containing low levels of HBoV. To further investigate this ﬁnding,
limited sequencing studies were performed using a newly devel-
oped semi-nested PCR assay speciﬁc for the HBoV NS1 gene that
ampliﬁes all 4 recognized HBoV types (protocol available from X.L.
upon request). Of the 49 specimens positive for HBoV by both in-
house and FTDRP assays, 36 of 37 (mean in-house Ct 26.6; range
13.3–37.3) were successfully sequenced (all HBoV type 1). In con-
trast, only 2 of 4 in-house assay positive (mean Ct 37.7; range
Ct 37.3–38.4)/FTDRP negative and none of the 20 FTDRP positive
(mean Ct 38.2; range Ct 36.3–39.9)/in-house negative specimens
could be conﬁrmed by NS1 PCR and sequencing. Failure to resolve
these discrepancies may  be due to (i) a higher sensitivity of the
FTDRP assay with specimens containing low levels of HBoV DNA,
possibly attributable to the larger volume of TNA extract used in
the FTDRP assay (10 L vs. 5 L), (ii) failure of both assays to detect
some variant HBoV strains and/or (iii) non-speciﬁc ampliﬁcation or
amplicon contamination in these samples.
The FTDRP EV/PeV assay also appeared to be more sensitive and
speciﬁc than the corresponding in-house EV assay with some spec-
imens. Of 18 specimens positive by the FTDRP EV/PeV assay (mean
Ct 34.6; range 29.9–38.4), and negative by in-house EV and PeV
assays, 9 had recoverable VP1 and/or VP4/2 sequences represent-
ing 8 different EVs (echovirus 6, 24, 30; enterovirus 68; poliovirus
1; coxsackievirus A4, B1, B4); 3, that were also positive by in-house
and FTDRP RV assays (Ct < 30), had sequence-conﬁrmed species A
RV of which 2 also had type-indeterminate EV sequences present;
1 gave a ﬂuorescence ampliﬁcation curve with the in-house PeV
assay, but with a Ct value >40 and therefore was classiﬁed as PeV
negative; and 5 could not be sequenced. Of 9 samples positive by
the in-house EV assay and negative by the FTDRP EV/PeV assay, all
were strongly positive for RV (Ct < 30) by both in-house and FTDRP
RV assays and were conﬁrmed positive for RV species A or C by VP1
and/or VP4/2 sequences. All 12 specimens positive by the in-house Ta
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Table  6
FTDRP and in-house assay sensitivity, speciﬁcity and Kappa values with 308 prospectively tested respiratory specimens.
Virusa FTDRPb In-houseb Kappa statisticc (95% CI)
Sensitivity Speciﬁcity Sensitivity Speciﬁcity
AdV 43.7 100.0 100.0 82.0 0.527 (0.405–0.648)
CoV 229E 100.0 99.7 85.7 100.0 0.921 (0.767–1)
CoV OC43 82.6 100.0 100.0 98.6 0.898 (0.798–0.997)
CoV NL63 100.0 100.0 100.0 100.0 1.(1–1)
EV/PeVd 80.0 93.2 66.7 96.5 0.676 (0.559–0.793)
HBoV 92.5 92.2 71.0 98.3 0.756 (0.662–0.85)
HMPV 74.6 100.0 100.0 93.4 0.822 (0.739–0.904)
Inf  A 96.7 100.0 100.0 99.6 0.981 (0.946–1)
Inf  B 93.3 100.0 100.0 100.0 0.964 (0.893–1)
PIV  1 69.2 100.0 100.0 98.7 0.812 (0.628–0.995)
PIV  2 100.0 100.0 100.0 100.0 1.(1–1)
PIV  3 96.2 100.0 100.0 99.2 0.977 (0.945–1)
PIV  4 100.0 99.3 80.0 100.0 0.886 (0.728–1)
RSV  72.5 100.0 100.0 88.0 0.780 (0.702–0.857)
RV  75.5 98.5 96.4 88.4 0.780 (0.704–0.856)
All  assays 77.0 98.8 91.3 96.5 0.812 (0.786–0.838)
a Virus co-detections included in the analysis.
b Referenced to FTDRP or in-house assay.
c Kappa statistic: <0–0.2 = poor; 0.21–0.4 = fair; 0.41–0.6 = moderate; 0.61–0.8 = good; and 0.81–1 = very good. CI, conﬁdence interval.
d FTDRP EV/PeV assay does not distinguish between EV and PeV.
PeV assay (mean Ct 33.8; range 27.7–38.4) were also positive by
the FTDRP EV/PeV assay with similar Ct values.
4. Discussion
Diagnosis of ARI in both clinical care and public health settings
has greatly advanced in recent years with the increased availability
of rapid, sensitive and speciﬁc molecular tests for the simultane-
ous detection of multiple respiratory pathogens. Some commercial
assays in particular that have received FDA 510(k) clearance have
made substantial inroads into the diagnostic laboratory (Rand et al.,
2011). However, these assays are often costly, require dedicated
laboratory equipment, use highly multiplexed reactions where
individual assay performance may  be compromised, and can be
difﬁcult to modify quickly in response to the emergence of new
medically important virus strains, as occurred during the 2009
H1N1 inﬂuenza pandemic.
The commercial multiplex FTDRP real-time RT-PCR assay
addresses some of these limitations by offering a complete kit with
moderate throughput for detection of 16 respiratory viruses that
could be easily integrated into the workﬂow of laboratories using
conventional real-time PCR platforms. The FTDRP assay setup and
runtime requires approximately 2.5 h for 12 samples and controls
(assay reagents are aliquoted in 12 sample test units), excluding
sample extraction, and with a kit list price of $27.34/sample (PCR
enzyme kit costs not included). By combining assays into 5 multi-
plex reaction mixes, individual mixes could more easily modiﬁed
if needed without impacting the other mixes and could allow for
more efﬁcient targeted testing based on epidemiologic ﬁndings.
In this study, the FTDRP multiplex assay was  compared with in-
house singleplex assays corresponding to each of the test viruses.
Overall, the FTDRP and in-house assays performed comparably for
most viruses tested, particularly when the virus was abundant in
the sample (low Ct values). With exceptions noted below, most
discordant results were seen with samples containing lower con-
centrations of virus (high Ct values), suggesting that differences
in assay sensitivity near their detection limits was  responsible for
these discrepancies rather than failure of primer/probe hybridiza-
tion due to critical target sequence mismatches.
FTDRP assays for RSV, RV and AdV in particular showed lower
relative sensitivities than the corresponding in-house assays with
some clinical specimens. The FTDRP RV assay showed clear evi-
dence of dropouts with some RV strains (see further discussion
below), and some prospectively tested specimens were negative for
RSV and AdV, even when the viruses were abundant. It is notable
that these three FTDRP assays are combined in the same reac-
tion mix  and these three viruses showed the highest co-detection
rates by singleplex in-house in these specimens. It is possible that
competing ampliﬁcation reactions in some specimens containing
multiple virus targets may  have reduced the sensitivity of some
assays for low abundant targets. This may  have had a more notice-
able impact on detection of AdV, where a disproportionate number
of AdV positive specimens had lower virus loads. This would be
expected in a population comprised of infants and young children
where persistent low level AdV shedding is common.
Development of real-time RT-PCR assays that can detect all RV
and EV strains and distinguish between both groups is challeng-
ing due to the extensive sequence diversity within each group and
sequence similarity between some EV and RV strains. These data
conﬁrmed previous experience with the in-house EV and RV assays:
both assays cross-react with some RV and EV strains, particularly if
present in high copy number (Lu et al., 2008; Oberste et al., 2010).
Although this complicated efforts to evaluate the FTDRP EV/PeV and
RV assays, several conclusions can be drawn from these ﬁndings.
The FTDRP EV/PeV assay appeared to be more sensitive and speciﬁc
than the in-house assay for detection of some EV strains, including
the recently emergent EV68 (CDC, 2011), although cross-reactions
with some RV strains identiﬁed in the archived sample collection
could not be ruled out. Of particular concern, the FTDRP RV assay
was insensitive with some sequence conﬁrmed RV species B and C
strains. This ﬁnding suggests that critical primer/probe mismatches
with these viruses substantially diminished target ampliﬁcation
and/or probe hybridization. More extensive testing of culture puri-
ﬁed RV and EV strains will be necessary to assess the full extent of
this deﬁciency.
Limited discrepancy testing was conducted and focused primar-
ily on samples with large differences in Ct values between the
in-house and FTDRP assays. To resolve all discrepant results for
all assays would require extensive conﬁrmatory testing with addi-
tional molecular tests possessing equal or greater sensitivity than
those evaluated here, which was beyond the scope of this study.
Limited specimen volume prevented additional testing in some
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cases. The apparent false-positive results by either assay were most
likely true positives occurring as the result of the conditions noted
above.
Following completion of this work, Fast-track Diagnostics intro-
duced a new version of the FTDRP assay (FTD Respiratory Pathogens
21) that expands testing to include new respiratory pathogens and
modiﬁes of some of the existing assays to enhance performance
(Miriam Steimer, Fast-track Diagnostics, personal communication).
Given these changes, and the promising potential of the FTDRP mul-
tiplex assay for diagnosis of respiratory virus infections, further
studies with expanded sample collections are warranted.
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